SLNO | Soleno Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	47.86 - 50.33
52 Week Range	3.73 - 53.82
Beta	-3.18
Implied Volatility	73.46%
IV Rank	12.31%
Day's Volume	216,425
Average Volume	529,032
Shares Outstanding	38,871,600
Market Cap	1,886,827,464
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-11-13

Valuation
Profitability
Growth
Health
P/E Ratio	-26.52
Forward P/E Ratio	-4.58
EPS	-1.83
1YR Price Target	8.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	33
Country	USA
Website	SLNO

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.

SLNO's peers: AIM, AKTX, BRTX, CAPR, CLLS, PPBT, PULM, SEEL, ANNX, ICVX, VECT, BOLT, LYRA, DFFN, ONTX, CBIO, BPTH, MBRX, DAWN, ABOS, XFOR, INZY, AMTI, ALRN, BNTC

*Chart delayed

Analyzing fundamentals for SLNO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see SLNO Fundamentals page.

Watching at SLNO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SLNO Technicals page.